Our board

Charles is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He holds Non-Executive Chairman positions at Creo Medical Group plc, MJ Hudson plc and Korn Wall Limited. In addition, he chairs the UK Department of Health Invention for Innovation Funding Panel.
Appointment to Board:
October 2013

Giulio has over thirty years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at Thermo Fisher Scientific, Inc. and LGC Ltd, where he transformed the scale of LGC’s Genomics division, completing 3 acquisitions in under eighteen months. Giulio was a member of the executive leadership team responsible for the successful sale of LGC Ltd to global investment firm, KKR & Co. Inc.
Appointment to Board:
February 2017

Grant has worked in the life sciences sector for over 15 years. In his executive director role, Grant leads the Company's Finance, Legal and IT functions. Grant joined IXICO from UK Biobank, an international health research data resource, where he had been Finance Director since 2014. Previous to this he was SVP Finance at Evotec, the early stage drug discovery CRO. Grant is a member of the Share Transaction Committee and also acts as Secretary to the Board and its subcommittees.

Appointment to Board:
August 2019

Mark is Chief Executive Officer of DeepMatter Group plc. He is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. Mark is Senior Independent Director and chairs the Remuneration Committee and Share Transaction Committee and is also a member of the Audit Committee.

Appointment to Board:
September 2016

Kate is qualified as a chartered accountant and holds a Bachelor of Science degree in Engineering from Oxford University.  Kate is currently leading the transformation of Glaxo SmithKline’s global finance organisation, having previously worked as CFO for Laboratoire Glaxo SmithKline SaS (GSK France) and prior held other senior finance roles during a 20 year career with GSK.  Kate chairs the Audit Committee and is a member of the Remuneration Committee. 

Appointment to Board:
January 2022